Why the Oncotype DX Breast Recurrence Score test?
Why the Oncotype DX Breast Recurrence Score test?
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak why they use Oncotype DX test and the invaluable information it provides on treatment decision-making for...
The Value of Oncotype DX Test in Early-Stage Breast Cancer
The Value of Oncotype DX Test in Early-Stage Breast Cancer
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak on the information Oncotype DX Breast Recurrence Score test provides and the value it provides for their...
Managing Breast Cancer During the COVID-19 Pandemic with the Oncotype DX Breast Recurrence Score® Test
Managing Breast Cancer During the COVID-19 Pandemic with the Oncotype DX Breast Recurrence Score® Test
Featuring speakers Christy Russell, MD (Sr. Medical Director, US Oncology) and Rick Baehner, MD (Chief Medical Officer, Precision Oncology).
How the Oncotype DX Breast Recurrence Score Makes a Difference in Treatment Decisions
How the Oncotype DX Breast Recurrence Score Makes a Difference in Treatment Decisions
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Christy Russell, Associate Professor of Clerical Oncology and Co-Director at the University...
Data Supporting Oncotype DX Test: TAILORx Trial
Data Supporting Oncotype DX Test: TAILORx Trial
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak on the results of the landmark TAILORx trial, and how the data guides treatment decisions for their breast...
TAILORx: Transforming the Treatment of Breast Cancer
TAILORx: Transforming the Treatment of Breast Cancer
Landmark TAILORx results, published on June 3rd, 2018, in the New England Journal of Medicine, demonstrate the Oncotype DX Breast Recurrence Score test definitively Identifies...
TAILORx - An Interview with Dr. Joe Sparano, Lead Investigator
TAILORx - An Interview with Dr. Joe Sparano, Lead Investigator
Published in the New England Journal of Medicine, the watershed TAILORx trial finds 99 percent of women with an Oncotype DX Breast Recurrence Score of 10...
Overview of the TAILORx Breast Cancer Clinical Trial
Overview of the TAILORx Breast Cancer Clinical Trial
At the 2013 San Antonio Breast Cancer Symposium: Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, is joined by Dr. Joseph Sparano, Associate Director, Clinical...
Genomic Testing Guidelines and Multidisciplinary Breast Cancer Treatment Decisions
Genomic Testing Guidelines and Multidisciplinary Breast Cancer Treatment Decisions
Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City discusses standardized breast cancer treatment and how the evolving...
What are the Oncotype DX Breast Recurrence Score Guidelines?
What are the Oncotype DX Breast Recurrence Score Guidelines?
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Christy Russell, Associate Professor of Clerical Oncology and Co-Director at the University of Southern...
Applying RxPONDER to Clinical Practice: Miami Breast Cancer Conference 2021 Product Theater
Applying RxPONDER to Clinical Practice: Miami Breast Cancer Conference 2021 Product Theater
At the 2021 Miami Breast Cancer Conference, Drs. Tari King and Kathy Miller discuss lymph node-positive breast cancer cases with Dr. Christy Russell.
Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test
Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test
Dr. Christy Russell, Senior Director of Medical Affairs at Exact Sciences, reviews data that were presented at SABCS 2020 "Enhancing the Utility of the Oncotype DX Breast Recurrence...
Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test
Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test
SABCS 2020 Virtual Product Theatre with speakers: Jeremy Force, DO; Alison Stopeck, MD; and Christy Russell, MD.
Using Oncotype DX Test to Change Management of Early-Stage Breast Cancer
Using Oncotype DX Test to Change Management of Early-Stage Breast Cancer
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak on how the Oncotype DX Breast Recurrence Score test has changed the management of early-stage breast cancer...
Integrating Oncotype DX Breast Recurrence Score Testing into Your Practice
Integrating Oncotype DX Breast Recurrence Score Testing into Your Practice
Dr. Virgina Kaklamani, Dr. Anthony Lucci and Dr. Jeremy Force speak on why they integrate Oncotype DX test into their practice.
Who Can Benefit from Oncotype DX Test?
Who Can Benefit from Oncotype DX Test?
Dr. Lucci, Dr. Kaklamani, and Dr. Force speak on which breast cancer patients can benefit from Oncotype DX test and how it is the ONLY test that identifies who may or may not...
Understanding the Oncotype DX Results
Understanding the Oncotype DX Results
Prepare for your appointment with your doctor to review your Oncotype DX Breast Recurrence Score results
Discussing the Breast Recurrence Score Results with Patients
Discussing the Breast Recurrence Score Results with Patients
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California, San...
Discussing the Oncotype DX Breast Recurrence Score Results with Patients
Discussing the Oncotype DX Breast Recurrence Score Results with Patients
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California, San...
Oncotype DX Breast Recurrence Score Test - What to Expect
Oncotype DX Breast Recurrence Score Test - What to Expect
Learn more about the Oncotype DX Breast Recurrence Score test and why your doctor ordered the test for you.
Genomic Profiling Reduces Patient Anxiety and Changes Treatment Decisions
Genomic Profiling Reduces Patient Anxiety and Changes Treatment Decisions
Knowing the biology of the breast cancer tumor and the genomic profiling can help reduce the anxiety of breast cancer patients by providing an in depth look at their disease...
Not All Breast Cancer Is The Same. Get Your Oncotype DX Recurrence Score
Not All Breast Cancer Is The Same. Get Your Oncotype DX Recurrence Score
Not all breast cancer is the same. Get your Oncotype DX score before you make your treatment decision.
Do you know your Oncotype DX Recurrence Score: Lynda
Do you know your Oncotype DX Recurrence Score: Lynda
Meet Lynda - Oncotype DX Recurrence Score 5.
Do You Know Your Oncotype DX Recurrence Score? - Mike
Do You Know Your Oncotype DX Recurrence Score? - Mike
Conoce a Mike - Oncotype DX Recurrence Score 3.
Do you know your Oncotype DX Recurrence Score: Susan
Do you know your Oncotype DX Recurrence Score: Susan
Meet Susan - Oncotype DX Recurrence Score 31.
Do you know your Oncotype DX Recurrence Score: Angela
Do you know your Oncotype DX Recurrence Score: Angela
Meet Angela - Oncotype DX Recurrence Score 22.
Do you know your Oncotype DX Recurrence Score: Coree
Do you know your Oncotype DX Recurrence Score: Coree
Meet Coree - Oncotype DX Recurrence Score 13.
Do you know your Oncotype DX Recurrence Score: Katherine
Do you know your Oncotype DX Recurrence Score: Katherine
Meet Katherine - Oncotype DX Recurrence Score 18.
Reggie Shares His Experience with His Wife's Breast Cancer and Oncotype DX Score
Reggie Shares His Experience with His Wife's Breast Cancer and Oncotype DX Score
Not all breast cancer is the same. Get your Oncotype DX score before you make your treatment decision. Diane's husband talks about his experience.
Using the Oncotype DX Breast Recurrence Score with the Treatment of Micrometastatic Disease
Using the Oncotype DX Breast Recurrence Score with the Treatment of Micrometastatic Disease
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Kathy Albain of the Loyola University Medical Center talk about treating micrometastatic breast cancer...
Using Oncotype DX Test in Management of Node-Positive Breast Cancer
Using Oncotype DX Test in Management of Node-Positive Breast Cancer
Dr. Jeremy Force, Professor of Breast Surgical Oncology at MD Anderson Cancer Center, speaks on value of the use of Oncotype DX Breast Recurrence Score test in node-positive...
The Oncotype DX Breast Recurrence Score and Patients with Trace Amounts of Cancer in Lymph Nodes
The Oncotype DX Breast Recurrence Score and Patients with Trace Amounts of Cancer in Lymph Nodes
The Oncotype DX Breast Recurrence Score and patients with small amounts of cancer detected in their lymph nodes is the topic when Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com,...
The Oncotype DX Breast Recurrence Score and Neoadjuvant Therapy Decisions
The Oncotype DX Breast Recurrence Score and Neoadjuvant Therapy Decisions
Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City, talks about how the Oncotype DX Breast Recurrence Score can determine...
How is the Oncotype DX Breast Recurrence Score Utilized in the Neoadjuvant Setting?
How is the Oncotype DX Breast Recurrence Score Utilized in the Neoadjuvant Setting?
Genomic Testing Guides DCIS Treatment Decisions
Genomic Testing Guides DCIS Treatment Decisions
The treatment of patients with DCIS breast cancer is analyzed by Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City. Dr....
Tools for Making Treatment Decisions DCIS Breast Cancer
Tools for Making Treatment Decisions DCIS Breast Cancer
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. David Hyams, Medical Director, Desert Surgical Oncology at the Eisenhower Medical Center, discuss ductal...
How the Breast DCIS Score is Being Utilized
How the Breast DCIS Score is Being Utilized
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California,...
Example of How the Breast DCIS Score is Helpful to Breast Cancer Patients
Example of How the Breast DCIS Score is Helpful to Breast Cancer Patients
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California,...
How Does the Oncotype DX Breast DCIS Score Help Determine the Aggressiveness of DCIS Breast Cancer?
How Does the Oncotype DX Breast DCIS Score Help Determine the Aggressiveness of DCIS Breast Cancer?
Dr. Rick Baehner talks about DCIS and invasive breast cancer and how the Breast DCIS Score identifies the aggressiveness of the cancer tumor tissue and the level of risk for...
The Utility of the Oncotype DX Breast DCIS Score
The Utility of the Oncotype DX Breast DCIS Score
Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Joseph Sparano, Associate Director, Clinical Research at the Albert Einstein Cancer Center;...
How Does the Oncotype DX Breast DCIS Score Revolutionize the Way DCIS Breast Cancer is Treated?
How Does the Oncotype DX Breast DCIS Score Revolutionize the Way DCIS Breast Cancer is Treated?
Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, describes how the Oncotype DX Breast DCIS Score is revolutionizing the way that DCIS breast cancer is being...
Oncotype DX Breast DCIS Score - Understanding Your Results
Oncotype DX Breast DCIS Score - Understanding Your Results
Prepare for your appointment with your doctor to review your Oncotype DX Breast DCIS Score results
How the Breast DCIS Score Result Is Helpful to Patients with DCIS
How the Breast DCIS Score Result Is Helpful to Patients with DCIS
Dr. Jay K. Harness sits down with Dr. Michael Alvarado to talk about a patient who benefited from the Oncotype DX Breast DCIS Score.
How Does the Oncotype DX Breast DCIS Score Work?
How Does the Oncotype DX Breast DCIS Score Work?
The Oncotype DX Breast DCIS Score is determined by examining a piece of breast cancer tumor tissue obtained at the time of surgery. Genomic Health's Senior Director of Pathology,...
What are the Benefits of the Oncotype DX Breast DCIS Score?
What are the Benefits of the Oncotype DX Breast DCIS Score?
Genomic Health Senior Director of Pathology Dr. Rick Baehner examines the benefits using the Oncotype DX Breast DCIS Score over other tools that are currently being used to...
Oncotype DX Breast DCIS Score - What to Expect
Oncotype DX Breast DCIS Score - What to Expect
Learn more about the Oncotype DX DCIS Score test and why your doctor ordered the test for you.
Who Should DCIS Breast Cancer Patients Talk to About Getting an Oncotype DX Breast DCIS Score?
Who Should DCIS Breast Cancer Patients Talk to About Getting an Oncotype DX Breast DCIS Score?
Patients diagnosed with DCIS breast cancer should talk to their surgeon or radiation oncologist about ordering the Oncotype DX test so they can get a Breast DCIS Score and determine...
What are the Treatment Options for Patients Diagnosed with DCIS Breast Cancer?
What are the Treatment Options for Patients Diagnosed with DCIS Breast Cancer?
Genomic Health's Dr. Rick Baehner, Senior Director of Pathology, reviews the various treatment options for those diagnosed with DCIS breast cancer. The Oncotype DX Breast DCIS...
Do you know your Oncotype DX DCIS Score: Jen
Do you know your Oncotype DX DCIS Score: Jen
Meet Jen - Oncotype DX DCIS Score 42.
Oncotype DX DCIS Breast Cancer Score: Amy's Story
Oncotype DX DCIS Breast Cancer Score: Amy's Story
Amy, a breast cancer survivor, describes her experience using the Oncotype DX Breast DCIS Score to personalize her treatment options. Share this video with your loved ones to...
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Your Oncotype DX Genomic Prostate score will arm you with information that'll help you take charge of your cancer treatment decision with confidence.
Data supporting the Oncotype DX GPS test in racially diverse populations
Data supporting the Oncotype DX GPS test in racially diverse populations
African-American men are more likely to be diagnosed with prostate cancer than European American men. The Oncotype DX GPS test can help make more informed treatment decisions and...
A Urologist's Experience with Oncotype DX GPS
A Urologist's Experience with Oncotype DX GPS
Ketan Badani, MD teaches and practices urology at Mount Sinai. Hear how the Oncotype DX GPS test helps him feel much more confident in treatment option discussions with patients.
mpMRI and the Genomic Prostate Score™ Assay
mpMRI and the Genomic Prostate Score™ Assay
For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology...
Prostate cancer case study with the Oncotype DX GPS™ test
Prostate cancer case study with the Oncotype DX GPS™ test
See how the Oncotype DX Genomic Prostate Score® test revealed aggressive tumor biology for a patient who initially seemed like a strong candidate for active surveillance.
How do you use the GPS™ report? The value of the GPS™ assay.
How do you use the GPS™ report? The value of the GPS™ assay.
Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS™ report in his practice.
For patients with clinically low-risk prostate cancer (very...
How do you use the short-term GPS™ report endpoint, Adverse Pathology?
How do you use the short-term GPS™ report endpoint, Adverse Pathology?
Doctors Scott Sellinger (Advanced Urology Institute) and Brian Helfand (NorthShore Medical Group) explain why adverse pathology is important in helping patients decide next steps...
Oncotype DX Genomic Prostate Score - Understanding Your Results
Oncotype DX Genomic Prostate Score - Understanding Your Results
Prepare for your appointment with your doctor to review your Oncotype DX Genomic Prostate Score results
Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer
Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer
See how men with unfavorable intermediate-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the Genomic Prostate Score...
Oncotype DX Genomic Prostate Score Test -- What to Expect
Oncotype DX Genomic Prostate Score Test -- What to Expect
Learn more about the Oncotype DX GPS test and why your doctor ordered the test for you.
Oncotype DX GPS Test - Understanding Your Results for Unfavorable Intermediate Risk Prostate Cancer
Oncotype DX GPS Test - Understanding Your Results for Unfavorable Intermediate Risk Prostate Cancer
Prepare for your appointment with your doctor to review your Oncotype DX Genomic Prostate Score results for men with unfavorable intermediate risk prostate cancer.
Jim's Story
Jim's Story
Do you know your Oncotype DX Genomic Prostate Score result? Watch Jim tell his prostate cancer story.
Your Prostate, Your Decision: A Patient's Perspective
Your Prostate, Your Decision: A Patient's Perspective
A prostate cancer patient shares his story to help raise awareness that men need to gather all the facts before choosing surgery after a prostate cancer diagnosis.
Lloyd and His Wife Discuss Prostate Cancer Treatments
Lloyd and His Wife Discuss Prostate Cancer Treatments
When it comes to prostate cancer, communication is vital, not only with a patient's doctor, but with their partner as well. We join Lloyd and his wife as they, with the help of...
Your Prostate, Your Decision: A Wife's Perspective
Your Prostate, Your Decision: A Wife's Perspective
A prostate cancer patient and his wife share their story to raise awareness that men need to get all the facts before choosing surgery after receiving a prostate cancer diagnosis.
Oncotype DX AR-V7 Nucleus Detect test
Oncotype DX AR-V7 Nucleus Detect test
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect...
Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test
Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test
This webinar explains what metastatic castration-resistant prostate cancer (mCRPC) is and how it is currently treated. In addition it will explain the role of resistance to androgen...
AR-V7 Case Study – Chemotherapy
AR-V7 Case Study – Chemotherapy
Learn how one physician decided on chemotherapy after assessing his patient’s AR-V7 status using the Oncotype DX AR-V7 Nucleus Detect test.
AR-V7 Case Study – Sequential AR-targeted therapy
AR-V7 Case Study – Sequential AR-targeted therapy
Discover how the Oncotype DX AR-V7 Nucleus Detect test helped a physician decide on sequential AR-targeted therapy for his patient.
AR-V7 Case Study – Post chemotherapy AR-targeted therapy
AR-V7 Case Study – Post chemotherapy AR-targeted therapy
Discover how one physician used the Oncotype DX AR-V7 Nucleus Detect test to understand his patient’s AR-V7 status, leading him to confidently choose another AR-targeted therapy...
AR-V7 Case Study – AR-targeted in M0 CRPC
AR-V7 Case Study – AR-targeted in M0 CRPC
Discover how one practitioner used the Oncotype DX AR-V7 Nucleus Detect® test to determine next steps for an mCRPC patient following failure of an AR-targeted therapy in M0 CPRC.
Oncotype DX Patient Bryce Shares His Metastatic Prostate Cancer Story
Oncotype DX Patient Bryce Shares His Metastatic Prostate Cancer Story
After diagnosed with metastatic prostate cancer at age 44, Bryce took an active role in his care, learning about all his options and tools to guide his treatment, including...
How do you manage mCRPC patients?
How do you manage mCRPC patients?
Leading physicians share insights into mCRPC disease management and how they navigate the rapidly evolving treatment landscape in advanced prostate cancer.
How do you define AR-targeted therapy failure?
How do you define AR-targeted therapy failure?
Learn what top physicians look for to help determine AR-targeted therapy failure.
mCRPC treatment management post AR-targeted therapy failure
mCRPC treatment management post AR-targeted therapy failure
Your patient fails an AR-targeted therapy. What's next? Leading physicians share insights into how they determine next treatment.
How does AR-V7 guide treatment decisions in mCRPC?
How does AR-V7 guide treatment decisions in mCRPC?
Find out how AR-V7 testing helps physicians guide treatment decisions for their mCRPC patients based on easy to interpret results.
Sequencing therapies in mCRPC patients
Sequencing therapies in mCRPC patients
Learn what top physicians look for when sequencing therapies in mCRPC patients.
Do you refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)?
Do you refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)?
Listen to leading physicians discuss the NCCN guidelines® updates and how they incorporate these into their practices for patient management in mCRPC.
AR-V7 testing in mCRPC: A case study
AR-V7 testing in mCRPC: A case study
A leading physician describes how the AR-V7 Nucleus Detect® test helped him make a personalized treatment decision for his mCRPC patient after the patient failed an AR-targeted...
Genomic Health and Oncotype IQ™ – Delivering Precision Medicine
Genomic Health and Oncotype IQ™ – Delivering Precision Medicine
Watch how Genomic Health continues to transform cancer care around the world.
Oncotype DX® Colon Cancer Patient Experience: Interview with Dan C.
Oncotype DX® Colon Cancer Patient Experience: Interview with Dan C.
Dan was diagnosed with stage-II colon cancer. After his tumor was assessed with Genomic Health's Oncotype DX Colon Recurrence Score, he and his doctor were able to create an individualized...
Dan C: His Treatment Decision
Dan C: His Treatment Decision
Dan C. explains why the Oncotype DX Colon Recurrence Score was helpful in his treatment decision.
Dan C: Newly Diagnosed Patients
Dan C: Newly Diagnosed Patients
Dan C. offers advice about the Oncotype DX Colon Recurrence Score for newly diagnosed patients.
Dan C: Describing His Treatment for Stage 2 Colon Cancer
Dan C: Describing His Treatment for Stage 2 Colon Cancer
Dan C. discusses his treatment for stage 2 colon cancer after using the Oncotype DX Colon Recurrence Score.
Stage II Colon Cancer: Clinical and Economic Utility of the Oncotype DX Colon Recurrence Score
Stage II Colon Cancer: Clinical and Economic Utility of the Oncotype DX Colon Recurrence Score
Dr. Steven Alberts discusses the Clinical and Economic Utility of the Oncotype DX Colon Recurrence Score in the MCCRC study.
Dr. David Kerr: How the Oncotype DX Helps Patient Discussions
Dr. David Kerr: How the Oncotype DX Helps Patient Discussions
The Oncotype DX Colon Recurrence Score from Genomic Health provides additional information to doctors on possible patient options for treatment, as detailed by Dr. David Kerr in...
An Oncotype DX Colon Recurrence Score Story
An Oncotype DX Colon Recurrence Score Story
The Oncotype DX Colon Recurrence Score from Genomic Health is a test that helps assess recurrence risk for colon cancer patients with stage II of the disease and appropriate stage...
Oncotype DX Colon Recurrence Score Overview: Lab Overview with Patient Dan and Dr. Kerr
Oncotype DX Colon Recurrence Score Overview: Lab Overview with Patient Dan and Dr. Kerr
The Oncotype DX Colon Recurrence Score from Genomic Health is a personalized diagnostic test that helps determine the likelihood the cancer may return.
Dr. George Kim: How Long Does It Take to Get the Colon Recurrence Score Results?
Dr. George Kim: How Long Does It Take to Get the Colon Recurrence Score Results?
Dr. George Kim discusses the Oncotype DX Colon Recurrence Score and the wait time to receive the results.
Dr. George Kim: What Is the Oncotype DX Colon Recurrence Score?
Dr. George Kim: What Is the Oncotype DX Colon Recurrence Score?
Dr. George Kim talks about the Oncotype DX Colon Recurrence Score and its role in determining treatment for colon cancer.
Dr. George Kim: When Do You Order the Test?
Dr. George Kim: When Do You Order the Test?
Dr. George Kim talks about the Oncotype DX Colon Recurrence Score and the ideal time to order the test.
Dr. George Kim: Who Is a Candidate for the Oncotype DX Colon Recurrence Score?
Dr. George Kim: Who Is a Candidate for the Oncotype DX Colon Recurrence Score?
Dr. George Kim discusses the Oncotype DX Colon Recurrence Score and who would be the best candidates for the test.
Dr. George Kim: Why Is the Test Valuable?
Dr. George Kim: Why Is the Test Valuable?
Dr. George Kim discusses the Oncotype DX Colon Recurrence Score and the value it has in determining the best course of treatment for colon cancer.
Dr. George Kim: Details of the MCCRC Study
Dr. George Kim: Details of the MCCRC Study
Dr. George Kim, Gastrointestinal Medical Oncologist, an author on the recently published prospective clinical utility study, discusses the MCCRC study, showing 45% change in treatment...
Dr. Mark Kozloff: What is the Oncotype DX Colon Recurrence Score?
Dr. Mark Kozloff: What is the Oncotype DX Colon Recurrence Score?
Dr. Mark Kozloff talks about the value of Oncotype DX to assist doctor-patient discussions about treatment options. He speaks to the absolute benefit as a function of risk.
Dr. Mark Kozloff: The Oncotype DX Colon Recurrence Score Helps Personalize Treatment
Dr. Mark Kozloff: The Oncotype DX Colon Recurrence Score Helps Personalize Treatment
Dr. Mark Kozloff discusses the Oncotype DX Colon Recurrence Score and how it helps personalize treatment for colon cancer patients.
Dr. Mark Kozloff: How Is the Test Validated?
Dr. Mark Kozloff: How Is the Test Validated?
Dr. Mark Kozloff discusses an overview of the independent validation process for the Oncotype DX Colon Recurrence Score.
Dr. Mark Kozloff: How Do You Describe the Test to Patients?
Dr. Mark Kozloff: How Do You Describe the Test to Patients?
Dr. Mark Kozloff discusses how he explains the Oncotype DX Colon Recurrence Score to patients.
Dr. Elisabeth McLemore and Dr. Kelly Shimabukuro: Case Study
Dr. Elisabeth McLemore and Dr. Kelly Shimabukuro: Case Study
Dr. Elisabeth McLemore and Dr. Kelly Shimabukuro talk about personalized risk assessment and evaluating patients with stage II colon cancer.
Dr. David Hyams: Personalized Treatment with the Colon Recurrence Score
Dr. David Hyams: Personalized Treatment with the Colon Recurrence Score
Dr. David Hyams, surgical oncologist, Desert Regional Medical Center, describes how he utilizes the Colon Recurrence Score report with his patients to discuss their personalized...
Dr. Mark Gimbel: What Is the Oncotype DX Colon Recurrence Score?
Dr. Mark Gimbel: What Is the Oncotype DX Colon Recurrence Score?
Dr. Mark Gimbel discusses the Oncotype DX Colon Recurrence Score and how it helps patients individualize their treatment plan.
Integrating Colorectal Surgeons into Multidisciplinary Care
Integrating Colorectal Surgeons into Multidisciplinary Care
Cary Gentry, MD, Colon and Rectal Specialists, LTD, Richmond, Virginia discusses how he standardizes risk assessment for Stage II, T3, MMR-P colon cancer patients with the Oncotype...
Making Treatment Decisions for Stage II Colon Cancer Patients with Histopathologic Features Only
Making Treatment Decisions for Stage II Colon Cancer Patients with Histopathologic Features Only
Dr. Howard Hochster, Dr. Deborah Nagle, and Dr. Darren Wheeler discuss issues with using histopathologic features alone for recurrence risk stratification and treatment selection...
Colon Cancer Roundtable: Dilemmas in Determining Treatment Decisions with Stage II Colon Cancer
Colon Cancer Roundtable: Dilemmas in Determining Treatment Decisions with Stage II Colon Cancer
Dr. Howard Hochster, Dr. Deborah Nagle and Dr. Darren Wheeler take a multi-disciplinary approach to discuss the challenges of risk assessment and treatment planning for stage II...
Colon Cancer Roundtable: Determining Recurrence Risk with Pathologic Features and Genomic Analysis
Colon Cancer Roundtable: Determining Recurrence Risk with Pathologic Features and Genomic Analysis
Dr. Howard Hochster, Dr. Deborah Nagle, and Dr. Darren Wheeler discuss the need to move beyond clinicopathologic features to provide a more individualized risk of recurrence.
Colon Cancer Roundtable: The Clinical Utility of the Oncotype DX Colon Recurrence Score
Colon Cancer Roundtable: The Clinical Utility of the Oncotype DX Colon Recurrence Score
Dr. Howard Hochster, Dr. Deborah Nagle, and Dr. Darren Wheeler discuss the development, validation, and clinical utility studies of the Oncotype DX Colon Recurrence Score.
Colon Cancer Roundtable: The Oncotype DX Colon Recurrence Score in Clinical Practice
Colon Cancer Roundtable: The Oncotype DX Colon Recurrence Score in Clinical Practice
Dr. Howard Hochster, Dr. Deborah Nagle, and Dr. Darren Wheeler discuss how they incorporate the Oncotype DX Colon Recurrence Score into their workflows . They discuss a few patient...
Dr. John Marshall: Genomics in Individualized Colon Cancer Treatment
Dr. John Marshall: Genomics in Individualized Colon Cancer Treatment
Dr. John Marshall discusses colon cancer and balancing the risk of treatment vs. the risk of no treatment, and how Oncotype DX offers genomic information personalized to each individual.
Dr. Ian Lavery: Not All Stage II Colon Cancer Patients Need Same Treatment
Dr. Ian Lavery: Not All Stage II Colon Cancer Patients Need Same Treatment
The Oncotype DX Colon Recurrence Score from Genomic Health is discussed by Dr. Ian Lavery, in which he says the extra information from Oncotype DX personalizes the treatment decisions.
Dr. Richard Goldberg: Colon Cancer Symtoms, Treatment and Using Oncotype DX Colon Recurrence Score
Dr. Richard Goldberg: Colon Cancer Symtoms, Treatment and Using Oncotype DX Colon Recurrence Score
Colon cancer and the Oncotype DX Colon Recurrence Score from Genomic Health are discussed when Dr. Richard Goldberg visits a talk show on Lifetime Television.
Dr. George Kim: Do All Colon Cancer Patients Need Chemotherapy?
Dr. George Kim: Do All Colon Cancer Patients Need Chemotherapy?
Dr. George Kim discusses the Oncotype DX Colon Recurrence Score and whether or not all colon cancer patients need chemotherapy as part of their treatment.
Dr. Mark Kozloff: What Wisdom Do You Try to Pass on to Other Physicians?
Dr. Mark Kozloff: What Wisdom Do You Try to Pass on to Other Physicians?
Dr. Mark Kozloff talks about the Oncotype DX Colon Recurrence Score and what he tells other physicians about the test.
Overview of the Oncotype MAP Pan-Cancer Tissue Test
Overview of the Oncotype MAP Pan-Cancer Tissue Test
Explore the benefits of the Oncotype MAP Pan-Cancer Tissue test, a rapid, comprehensive genomic profiling panel that aids therapy selection for patients with advanced, metastatic,...
Explore the Benefits of the Oncotype MAP Pan-Cancer Tissue Test for Physicians
Explore the Benefits of the Oncotype MAP Pan-Cancer Tissue Test for Physicians
Hear from Drs. Ariane Kemkes and Scott Morris on the unique benefits of the Oncotype MAP Pan-Cancer Tissue test for healthcare professionals.
Levels of Evidence & Curation Process for the Oncotype MAP Pan-Cancer Tissue Test
Levels of Evidence & Curation Process for the Oncotype MAP Pan-Cancer Tissue Test
Learn more about the levels of evidence, curation process, and quality control system behind the Oncotype MAP Pan-Cancer Tissue test from Dr. Ariane Kemkes.
Lab Week Pathology Webinar with Drs. Rick Baehner and Josh Routh
Lab Week Pathology Webinar with Drs. Rick Baehner and Josh Routh
Learn about the Oncotype MAP Pan-Cancer Tissue test from a Pathologist’s Perspective.
Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling
Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling
USCAP 2021 Oncotype MAP Pan-Cancer Tissue Test Symposium, presented by Rick Baehner, MD and Joshua Routh, MD.